
Bristol-Myers Squibb appoints Charles Bancroft acting chief financial officer
pharmafile | January 15, 2010 | Appointment | Sales and Marketing | BMS, appointment, sales and marketing
Charles Bancroft has been appointed acting chief financial officer at Bristol-Myers Squibb, replacing Jean-Marc Huet who left the company at the end of 2009
Chairman and chief executive of Bristol-Myers Squibb James Cornelius said: “Jean-Marc has indicated to me his desire to return to Europe and we wish him every success.
“The board of directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet, his focus on increasing our cash position to nearly $10 billion through a series of important transactions, and his leadership of continuous improvement initiatives which have greatly accelerated our BioPharma transformation.”
His replacement, Charles Bancroft, was most recently vice president, finance for Bristol-Myers Squibb’s global biopharmaceutical business.
In his new role, Bancroft will continue to report to Lamberto Andreotti, president and chief operating officer.
Bancroft joined Bristol-Myers in 1984 and has since held positions of increasing responsibility within the finance organisation, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec.
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …






